• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to the field of healthcare, namely, to the treatment of socially significant diseases, such as complications of diabetes mellitus, atherosclerosis, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases including Alzheimer's and Parkinson's diseases, cataract, age-related diseases, etc.The essence of the invention is the use of sulfasalazine (international non-proprietary name; synonyms: Salazosulfapyridine, Azopyrine, Asulfidine, Salazopyridin, Salazopyrin, Salazosulfapyridine, Salicylazosulfapyridin, Salisulf, Sulfasalazyn, Sulphasalazine) of the general formula I as an inhibitor of the formation of advanced glycation end-products:
    公开号:EP3695842A1
    申请号:EP18866610.1
    申请日:2018-10-11
    公开日:2020-08-19
    发明作者:Yurij Grigorevich SHTYRLIN；Aleksandr Alekseevich SPASOV；Konstantin Valerevich BALAKIN；Valentina Andreevna KUZNETSOVA；Vladimir Ivanovich Petrov；Aleksej Dmitrievich STRELNIK
    申请人:Ltd Co Research And Development Co "medbiopharm"；
    IPC主号:A61P3-00
    专利说明:
    [0001] The invention relates to the use of Sulfasalazine (international non-proprietary name; synonyms: Salazosulfapyridine, Azopyrine, Asulfidine, Salazopyridin, Salazopyrin, Salazosulfapyridine, Salicylazosulfapyridin, Salisulf, Sulfasalazyn, Sulphasalazine) of general formula I for a new purpose as an inhibitor of the formation of advanced glycation end-products (hereinafter, AGEs):
    [0002] Sulfasalazine I is an effective inhibitor of the formation of glycation end products and can be widely used in medicine in the treatment of socially significant diseases, namely, complications of diabetes mellitus, atherosclerosis, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, cataracts, age related diseases, etc.
    [0003] A prior art study by the applicant revealed that sulfasalazine was introduced to the market in the 1950s as a treatment for rheumatoid arthritis, Crohn's disease and ulcerative colitis ([1] M.A. Peppercorn, Ann. Intern. Med., 1984, 101: 377-386; [2] G.L. Plosker, K.F. Croom, Drugs, 2005, 65: 1825-1849). The mechanism of action of sulfasalazine and its metabolites is associated primarily with the inhibition of the activation of nuclear factor kappa B (NFKB), which is contained in cells of all types and is associated with the development of inflammatory and autoimmune diseases, as well as septic shock. Sulfasalazine can accumulate in the connective tissue of the intestine with the release of 5-aminosalicylic acid, which has an anti-inflammatory effect, and sulfapyridine, which has an antimicrobial effect against diplococci, streptococci, gonococci, and Escherichia coli.
    [0004] However, an analysis of literature and patent information sources did not reveal information about the antiglycan activity of sulfasalazine. Thus, the prior art analysis by the applicant did not reveal any data on the possibility of using Sulfasalazine (Formula I) or its saline and co-crystalline forms as inhibitors of the formation of advanced glycation end products.
    [0005] Glycation (non-enzymatic glycosylation, Maillard reaction) is a chemical reaction in which the carbonyl groups of reduced sugars bind to the amino groups of long-lived proteins, lipids or peptides, with the formation of advanced glycation end-products (AGEs) ([3] S. Khangholi, F.A. Abdul Majid, N.J.A. Berwary, F. Ahmad, R. Bin Abd Aziz, Planta Med., 2016; 82: 32-45; [4] V.P. Singh, A. Bali, N. Singh, A.S. Jaggi, Korean J. Physiol. Pharmacol., 2014, 18: 1-14).
    [0006] At the same time, intracellular and extracellular accumulation of AGEs is considered an important factor in the pathogenesis of diseases, such as atherosclerosis ([5] M. Busch, S. Franke, C. Rüster, G. Wolf, European Journal of Clinical Investigation, 2010, 40(8): 742-755), heart failure, inflammation, rheumatoid arthritis and osteoarthritis, neurodegenerative diseases, including Alzheimer's and Parkinson's diseases ([6] J. Li, D. Liu, L. Sun, Y. Lu, Z. Zhang, Journal of the Neurological Sciences, 2012, 317: 1-5), other age-related diseases, and cataract ([7] I. Sadowska-Bartosz I,G. Bartosz, Mech. Ageing Dev. 2016, 160: 1-18). This process is very intense in diabetes mellitus, with the rate of AGEs formation depending on the concentration and duration of action of glucose ([8] R. Ramasamy, S.F. Yan, A.M. Schmidt, Ann. N. Y. Acad Sci., 2011, 1243: 88-102; [9] M. I. Balabolkin, Diabetes Mellitus, 2002, 4: 8-16). The effects of AGEs can be classified as receptor-independent or receptor-dependent, and AGEs can act intracellularly or circulate and act on cell surface receptors, such as receptor for advanced glycation end products (RAGE). Since glycation occurs over a long period of time, AGEs affect long-lived proteins. For example, the main targets for them are the structural components of connective tissue and, in particular, type IV collagen, as well as other long-lived proteins, including myelin, tubulin, crystallin, plasminogen activator 1, and fibrinogen, which can also undergo glycation ([10] S.-Y. Goh, M. E. Cooper. J Clin Endocrinol Metab, 2008, 93(4): 1143-1152). By binding to membrane RAGEs, glycation end-products activate certain intracellular signaling pathways leading to increased formation of pro-inflammatory cytokines, free radicals and chemoattractants ([3]; [11] S.C. Ho, P.W. Chang, Am. J. Plant. Sci., 2012, 3: 995-1002). All of the above is the basis of the pathogenesis of such consequences of diabetes mellitus as diabetic atherosclerosis, nephro-, neuro-, retino-, cardio-, and angiopathies, which account for the high risk of disability and mortality among patients with diabetes mellitus.
    [0007] The use of compounds with high antiglycation activity will reduce the formation of AGEs in the body, thereby improving the quality of life of patients by reducing the risk of atherosclerosis, cataract, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases including Alzheimer's and Parkinson's diseases, as well as such complications of diabetes mellitus as diabetic atherosclerosis, nephro-, neuro-, retino-, cardio-, and angiopathies, which account for the high risk of disability and mortality among patients with diabetes mellitus.
    [0008] All of the above arouses heightened worldwide interest in the search for inhibitors of advanced glycation end-products, since there are no drugs that specifically inhibit the formation of AGEs and are approved for clinical use in the world as of the date of submission of this application.
    [0009] The applicant's analysis of Russian and foreign patent databases, scientific literature and Internet resources showed that there are analogues of the claimed technical solution as to their intended purpose, which can inhibit the formation of AGEs yet have significant disadvantages, namely insufficient efficacy and/or significant undesirable effects, e.g. are highly toxic, etc.
    [0010] Further, the applicant provides information on the identified drugs that have reached the stage of clinical trials. The first and most studied substance of those inhibiting protein glycation is aminoguanidine (AG) ([12] A. Cerami, P.C. Ulrich, M. Brownlee, Pat US4758583A, published 19.07.1988 ). It is designed to prevent the formation of AGEs and glucose-derived cross-linked collagen molecules. The mechanism of the antiglycation action of aminoguanidine is associated with its ability to capture reactive dicarbonyl intermediates. However, clinical trials of this drug were stopped due to lack of efficacy and the presence of undesirable effects.
    [0011] Currently, clinical trials of pyridoxamine are being conducted ([13] R. Khalifah, B.G. Hudson, Pat US6716858B1, published 06.04.2004 ). Pyridoxamine also has antiglycation properties, but it also shows low activity comparable to that of aminoguanidine, which has been withdrawn from clinical trials. As of the date of submission of this application, the applicant has not discovered any other analogues of the claimed technical solution used for its intended purpose and included in the stage of clinical trials.
    [0012] Thus, as of the date of submission of the application materials, the problem of creating highly active inhibitors of the formation of AGEs approved for clinical use remains unresolved not only in the Russian Federation, but also abroad.
    [0013] The claimed technical solution is illustrated by the following materials: Table 1 showing the antiglycation activity of sulfasalazine compared with the prototype (aminoguanidine). Table 2 showing the values of the 50% inhibitory concentration of sulfasalazine compared with the prototype (aminoguanidine).
    [0014] The object of the claimed technical solution is the search for new uses of known drugs having, in addition to the known field of application, high antiglycation activity, which ensures the accelerated market launch of the drug with a new therapeutic indication.
    [0015] The technical result of the proposed invention is the use of sulfasalazine (a well-known medication for the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis) as an inhibitor of the formation of AGEs, since it has a higher antiglycation activity compared to substances that have reached the stage of clinical trials.
    [0016] The essence of the proposed invention is the use of a well-known drug sulfasalazine of the general formula I as an inhibitor of the formation of AGEs, which has a higher antiglycation activity compared to the prototype (aminoguanidine):
    [0017] The glycation reaction is reproduced according to the method of A. Jedsadayanmata ([14] A. Jedsadayanmata, Naresuan University Journal, 2005, 13(2): 35-41). The reaction mixture contains solutions of bovine serum albumin (1 mg/ml) and glucose (500 mM) in phosphate buffer (pH = 7.4). To prevent bacterial growth, sodium azide in a final concentration of 0.02% is added to the buffer solution. All substances are dissolved in dimethyl sulfoxide (DMSO). 30 µ1 of sulfasalazine solution in various concentrations is added to the experimental samples; DMSO is added to the control samples in the same volume. All experimental samples are incubated for 24 hours at 60°C. At the end of the incubation period, specific fluorescence of glycated bovine serum albumin (BSA) is determined using an F-7000 spectrofluorimeter (Hitachi, Japan) at an excitation wavelength of 370 nm and an emission wavelength of 440 nm. As a comparison substance, a known glycation inhibitor aminoguanidine is used (Table 1) ([15] P.J. Thornalley, Archives of Biochemistry and Biophysics, 2003, 419: 31-40).
    [0018] Statistical processing of the results is carried out using the non-parametric Mann-Whitney test, the Microsoft Excel 2007 table editor and the GraphPad Prism 5.0 software. The calculation of the IC50 indicator is carried out by the method of regression analysis (Table 2). Table 1 The effect of sulfasalazine and aminoguanidine on BSA glycation at various concentrationsDrug concentration (mol) Drug name 10-3 3∗10-4 10-4 3∗10-5 10-5 - The average concentration of AGEs in the sample at a given concentration of the drug (Δ%, M±m) Sulfasalazine 98.94±0.20* 97.53±0.43* 81.60±7.18* 65.37±2.25* 43.42±4.21* Aminoguanidine 58.08±0.72* 50.25±0.72* 38.75±1.52* 19.14±2.24* 3.53±2.31* Note: * the data are reliable in relation to the positive control (Mann-Whitney test, p <0.05). Table 2 IC50 values for BSA glycation Substance IC50, µM Sulfasalazine I 23.90Aminoguanidine 765.00
    [0019] The analysis of the data shown in Table 1 and Table 2 allows us to conclude that sulfasalazine exhibits a high level of antiglycation activity (Table 1), which allows us to determine the dependence of its effect on concentration and calculate the IC50 index (Table 2).
    [0020] Thus, the results obtained by the applicant demonstrate that the activity of sulfasalazine significantly exceeds that of aminoguanidine, which allows us to consider it as an effective inhibitor of the formation of glycation end-products. At the same time, unlike aminoguanidine, sulfasalazine is an approved drug that has proven its high effectiveness and safety during many years of trials and clinical use.
    [0021] Based on the foregoing, we can conclude that the claimed technical solution allows to create new highly effective and safe drugs for the prevention and treatment of micro- and macrovascular complications of diabetes, atherosclerosis, neurodegenerative diseases, cataract, and age-related diseases, thereby improving the quality of life of patients.
    [0022] The claimed technical solution meets the criterion of "novelty" imposed on inventions, as the prior art study has not detected any technical solutions with the claimed combination of distinctive features that achieve the claimed results.
    [0023] The claimed technical solution meets the criterion of "inventive step" imposed on inventions, as it is not obvious to a specialist in this field of science and technology.
    [0024] The claimed technical solution meets the criterion of "industrial applicability", as it can be implemented at any specialized enterprise using standard equipment, well-known domestic materials and technologies.
    权利要求:
    Claims (1)
    [0001] The use of Sulfasalazine (international non-proprietary name; synonyms: Salazosulfapyridine, Azopyrine, Asulfidine, Salazopyridin, Salazopyrin, Salazosulfapyridine, Salicylazosulfapyridin, Salisulf, Sulfasalazyn, Sulphasalazine) of general formula I for a new purpose:
    类似技术:
    公开号 | 公开日 | 专利标题
    Miller-Fleming et al.2015|Remaining mysteries of molecular biology: the role of polyamines in the cell
    Wu et al.2016|An ancient, unified mechanism for metformin growth inhibition in C. elegans and cancer
    Henao-Mejia et al.2014|Inflammasomes and metabolic disease
    Matafome et al.2013|Methylglyoxal, obesity, and diabetes
    Fernández et al.2015|The functional and pathologic relevance of autophagy proteases
    Semchyshyn2014|Reactive carbonyl species in vivo: generation and dual biological effects
    Pecorelli et al.2013|NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells
    Deng et al.2013|Molecular mechanism responsible for the priming of macrophage activation
    Qi et al.2017|Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction
    Chaykovska et al.2011|Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy
    Barbagallo et al.2010|Magnesium and aging
    Aldini et al.2013|Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products
    Moridi et al.2015|Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes
    Cho et al.2007|The road to advanced glycation end products: a mechanistic perspective
    Brouwers et al.2014|Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes
    Harding et al.2003|An integrated stress response regulates amino acid metabolism and resistance to oxidative stress
    Koshlukova et al.1999|Salivary histatin 5 induces Non-lytic release of ATP fromCandida albicans leading to cell death
    Agalakova et al.2012|Molecular mechanisms of cytotoxicity and apoptosis induced by inorganic fluoride
    Beckman1996|Oxidative damage and tyrosine nitration from peroxynitrite
    Schorn et al.2011|Sodium overload and water influx activate the NALP3 inflammasome
    Panday et al.2015|NADPH oxidases: an overview from structure to innate immunity-associated pathologies
    Calderon-Salinas et al.2011|Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease
    Himmelfarb et al.2002|The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia
    Lukov et al.2005|Phosducin‐like protein acts as a molecular chaperone for G protein βγ dimer assembly
    Goldstein et al.2000|3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote α-crystallin cross-linking by metal ion reduction
    同族专利:
    公开号 | 公开日
    WO2019074406A1|2019-04-18|
    EA202090941A1|2020-07-03|
    EP3695842A4|2021-04-14|
    RU2680844C1|2019-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2019-04-19| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
    2020-07-17| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-07-17| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-08-19| AX| Request for extension of the european patent|Extension state: BA ME |
    2020-08-19| 17P| Request for examination filed|Effective date: 20200505 |
    2020-08-19| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2021-01-20| DAV| Request for validation of the european patent (deleted)|
    2021-01-20| DAX| Request for extension of the european patent (deleted)|
    2021-04-14| A4| Supplementary search report drawn up and despatched|Effective date: 20210315 |
    2021-04-14| RIC1| Information provided on ipc code assigned before grant|Ipc: A61K 31/635 20060101AFI20210309BHEP Ipc: A61P 43/00 20060101ALI20210309BHEP Ipc: A61P3/10 20060101ALI20210309BHEP Ipc: A61P 19/02 20060101ALI20210309BHEP Ipc: A61P 25/16 20060101ALI20210309BHEP Ipc: A61P 25/28 20060101ALI20210309BHEP Ipc: A61P 27/12 20060101ALI20210309BHEP |
    2022-02-18| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]